Trial Search Results

BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)

The purpose of this study is to measure how active BMS-936558 (nivolumab) is against Renal Cell Carcinoma (RCC) as measured by the disease not progressing and whether a dose response relationship exists.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Bristol-Myers Squibb

Collaborator: Ono Pharma USA Inc

Stanford Investigator(s):


  • Biological: nivolumab
  • Biological: nivolumab
  • Biological: nivolumab


Phase 2


For more information regarding BMS clinical trial participation, please visit

Inclusion Criteria:

   - Histologic confirmation of Renal cell carcinoma (RCC) with a clear cell component

   - Previous treatment with at least one anti-angiogenic agent

   - Progressed within 6 months of study enrollment

   - Subjects should not have had more than 3 prior treatments for locally advanced or
   metastatic disease

   - Must have available tumor tissue for submission

   - Subjects must also meet various laboratory parameters for inclusion

Exclusion Criteria:

   - Subjects with any active autoimmune disease or a history of known autoimmune disease

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
Not Recruiting